Author

Hagar Banai Eran

RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL
RESPONSIVENESS OF FECAL CALPROTECTIN AND QUALITY OF LIFE QUESTIONNAIRES TO CHANGE IN POUCH DISEASE ACTIVITY. RESULTS FROM A PROSPECTIVE TRIAL

Hagar Banai Eran  et al.

A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE
A SIMPLE WEB-BASED TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS USING EXPLAINABLE ARTIFICIAL INTELLIGENCE

Hagar Banai Eran  et al.

RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT
RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT

Hagar Banai Eran  et al.

EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS
EXTERNAL VALIDATION OF A NOVEL EXPLAINABLE AI-DERIVED WEB TOOL FOR PREDICTING DRUG SUSTAINABILITY OF INFLIXIMAB AND VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS

Hagar Banai Eran  et al.

FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT
FAVOURABLE FIRST YEAR REMISSION RATES AMONG PATIENTS WITH NEWLY DIAGNOSED CROHN'S DISEASE: DATA FROM A REAL-WORLD PROSPECTIVE INCEPTION COHORT

Hagar Banai Eran  et al.

Item 1 - 5 / 5
1